ProQR Therapeutics Closes $100M Public Offering
Ticker: PRQR · Form: 6-K · Filed: Dec 5, 2024 · CIK: 1612940
| Field | Detail |
|---|---|
| Company | Proqr Therapeutics N.V. (PRQR) |
| Form Type | 6-K |
| Filed Date | Dec 5, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: financing, public-offering, biotech
TL;DR
ProQR just closed a $100M public offering, raising cash to fund their RNA therapies.
AI Summary
On December 5, 2024, ProQR Therapeutics N.V. announced the closing of its previously announced underwritten public offering. The company successfully raised approximately $100 million in gross proceeds before deducting underwriting discounts and commissions and other offering expenses. This offering involved the sale of 13,333,333 ordinary shares at a price of $7.50 per share.
Why It Matters
The successful capital raise provides ProQR Therapeutics with significant funding to advance its pipeline of RNA therapies, potentially accelerating drug development and future clinical trials.
Risk Assessment
Risk Level: medium — While the capital raise is positive, the company operates in the highly speculative biotechnology sector with inherent risks in drug development and market approval.
Key Numbers
- $100.0M — Gross Proceeds (Funds raised from the public offering before expenses.)
- 13.3M — Shares Sold (Number of ordinary shares issued in the offering.)
- $7.50 — Price Per Share (The price at which each ordinary share was sold.)
Key Players & Entities
- ProQR Therapeutics N.V. (company) — Issuer of the 6-K filing and subject of the press release.
- December 5, 2024 (date) — Date of the press release and closing of the public offering.
- $100 million (dollar_amount) — Approximate gross proceeds raised from the public offering.
- 13,333,333 (number) — Number of ordinary shares sold in the offering.
- $7.50 (dollar_amount) — Price per ordinary share in the public offering.
FAQ
What was the total amount of gross proceeds raised by ProQR Therapeutics in the public offering?
ProQR Therapeutics raised approximately $100 million in gross proceeds from the underwritten public offering.
On what date did ProQR Therapeutics announce the closing of its public offering?
The press release announcing the closing of the public offering was issued on December 5, 2024.
How many ordinary shares did ProQR Therapeutics sell in the offering?
ProQR Therapeutics sold 13,333,333 ordinary shares in the public offering.
What was the price per ordinary share in the public offering?
The ordinary shares were sold at a price of $7.50 per share.
What is the primary purpose of the funds raised by ProQR Therapeutics?
The funds raised are intended to be used for general corporate purposes, which include advancing ProQR's pipeline of RNA therapies.
Filing Stats: 273 words · 1 min read · ~1 pages · Grade level 9.9 · Accepted 2024-12-05 08:04:31
Filing Documents
- tm2430208d1_6k.htm (6-K) — 12KB
- tm2430208d1_ex99-1.htm (EX-99.1) — 20KB
- 0001104659-24-125770.txt ( ) — 33KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. PROQR THERAPEUTICS N.V. Date: December 5, 2024 By: /s/ René Beukema René Beukema Chief Corporate Development Officer and General Counsel INDEX TO EXHIBITS Number Description 99.1 Press Release of ProQR Therapeutics N.V. dated December 5, 2024.